Article
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
The Lancet. Infectious diseases - 1 Jun 2015
Mizokami Masashi, Yokosuka Osamu, Takehara Tetsuo, Sakamoto Naoya, Korenaga Masaaki, Mochizuki Hitoshi, Nakane Kunio, Enomoto Hirayuki, Ikeda Fusao, Yanase Mikio, Toyoda Hidenori, Genda Takuya, Umemura Takeji, Yatsuhashi Hiroshi, Ide Tatsuya, Toda Nobuo, Nirei Kazushige, Ueno Yoshiyuki, Nishigaki Yoichi, Betular Juan, Gao Bing, Ishizaki Akinobu, Omote Masa, Mo Hongmei, Garrison Kim, Pang Phillip S, Knox Steven J, Symonds William T, McHutchison John G, Izumi Namiki, Omata Masao
Abstract excerpt
BACKGROUND: Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older, have more advanced liver disease, and are more likely to have been previously treated for hepatitis C. We aimed to assess the efficacy and safety of an all-oral, fixed-dose combination of the hepatitis C virus NS5A inhibitor ledipasvir and the NS5B nucleotide polymerase inhibitor sofosbuvir with and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.